Jul 09 2012
REDWOOD CITY, California—Proteus Digital Health and Otsuka Pharmaceutical (Tokyo) have entered into an exclusive worldwide license and collaboration agreement to make a new category of medicines. These new medicines will be based on Otsuka’s products and Proteus’s digital
health feedback system using Proteus’s novel sensor-based technologies.
Proteus and Otsuka have entered an exclusive collaboration to develop commercial products in two defined therapeutic areas of what they consider high unmet medical need. Otsuka has also been granted a non-exclusive license to use Proteus technology in its clinical research and
development activities. Financial terms of the agreement were not disclosed.
The Proteus digital health feedback system combines wearable and ingestible sensor technologies that together are designed to help improve patients’ health habits. Detailed information, including when a medication has been taken as well as activity and rest patterns, is captured and delivered to a secure database. The information, accessible from a variety of platforms such as mobile phones with consent granted by the patient, is designed to help patients and their caregivers better manage their conditions and to help clinicians provide more effective care.
Otsuka makes original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health.
Medical Device Daily